New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Ayurveda OPD will be established in 10 ECHS Polyclinic/Dispensaries in various regions of India to cover all ECHS members on a voluntary basis
The cloud platform will empower biotech companies and CROs with an integrated solution for clinical data management and is supported by Emmes specialist data management teams
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Subscribe To Our Newsletter & Stay Updated
